We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+0.56%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$100B
AUM Growth
-$9.45B
(-8.6%)
Cap. Flow
-$5.83B
Cap. Flow
% of AUM
-5.81%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
3,811
New
911
Increased
1,180
Reduced
974
Closed
681
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPYM
State Street SPDR Portfolio S&P 500 ETF
SPYM
|
+$3.97B |
| 2 |
Chevron
CVX
|
+$527M |
| 3 |
Apple
AAPL
|
+$449M |
| 4 |
Morgan Stanley
MS
|
+$426M |
| 5 |
Airbnb
ABNB
|
+$367M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$4.21B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$2.87B |
| 3 |
Walmart Inc
WMT
|
+$831M |
| 4 |
Amazon
AMZN
|
+$692M |
| 5 |
Eli Lilly
LLY
|
+$641M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Consumer Discretionary | 11.57% |
| 3 | Healthcare | 9.79% |
| 4 | Financials | 6.87% |
| 5 | Industrials | 5.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
ICU Medical
ICUI
$3.93B
| $3.45M | ﹤0.01% |
26,687
+25,187
| +1,679% | +$3.62M |
|
|
1477
CALL
Walmart Inc
WMT
$871B
| $3.44M | ﹤0.01% |
27,700
-128,900
| -82% | -$15.8M |
|
1478
Gain Therapeutics
GANX
$74.6M
| $3.43M | ﹤0.01% |
1,769,788
+107,495
| +6% | +$234K |
|
1479
Vertex
VERX
$1.92B
| $3.43M | ﹤0.01% |
288,636
+258,568
| +860% | +$4.03M |
|
1480
Yelp
YELP
$1.38B
| $3.42M | ﹤0.01% |
138,186
-18,565
| -12% | -$470K |
|
1481
Liberty Latin America Class A
LILA
$1.51B
| $3.42M | ﹤0.01% |
582,055
+210,349
| +57% | +$1.11M |
|
1482
CorMedix
CRMD
$617M
| $3.42M | ﹤0.01% |
502,965
-1,463,297
| -74% | -$10.8M |
|
1483
Galectin Therapeutics
GALT
$229M
| $3.4M | ﹤0.01% |
1,219,912
+617,778
| +103% | +$1.88M |
|
|
FLNA
1484
Filana Therapeutics
FLNA
$43M
| $3.4M | ﹤0.01% |
2,012,543
-102,764
| -5% | -$212K |
|
1485
Clarivate
CLVT
$1.3B
| $3.4M | ﹤0.01% |
1,343,271
+337,270
| +34% | +$863K |
|
|
NVMI
1486
Nova
NVMI
$13.9B
| $3.39M | ﹤0.01% |
+7,800
| New | +$3.44M |
|
1487
The Greenbrier Companies
GBX
$1.61B
| $3.38M | ﹤0.01% |
+64,246
| New | +$3.39M |
|
1488
CALL
Vistra
VST
$55.1B
| $3.37M | ﹤0.01% |
+22,400
| New | +$3.63M |
|
1489
Stratasys
SSYS
$697M
| $3.36M | ﹤0.01% |
430,695
+149,550
| +53% | +$1.46M |
|
1490
Kura Sushi USA
KRUS
$537M
| $3.35M | ﹤0.01% |
47,982
-12,612
| -21% | -$846K |
|
1491
Sylvamo
SLVM
$1.52B
| $3.35M | ﹤0.01% |
79,251
-14,699
| -16% | -$688K |
|
1492
TETRA Technologies
TTI
$1.23B
| $3.34M | ﹤0.01% |
392,407
-4,490
| -1% | -$45K |
|
|
BIOA
1493
BioAge Labs
BIOA
$968M
| $3.33M | ﹤0.01% |
190,472
-32,476
| -15% | -$625K |
|
1494
Structure Therapeutics
GPCR
$3.49B
| $3.33M | ﹤0.01% |
69,107
-99,477
| -59% | -$6.81M |
|
1495
Capricor Therapeutics
CAPR
$1.14B
| $3.33M | ﹤0.01% |
109,531
-12,381
| -10% | -$330K |
|
1496
Beam Therapeutics
BEAM
$2.58B
| $3.32M | ﹤0.01% |
139,241
-806,588
| -85% | -$22.4M |
|
1497
Compass Diversified
CODI
$755M
| $3.32M | ﹤0.01% |
421,861
-358,621
| -46% | -$2.28M |
|
1498
Cavco Industries
CVCO
$4.39B
| $3.31M | ﹤0.01% |
6,840
+1,797
| +36% | +$1.02M |
|
1499
Ultragenyx Pharmaceutical
RARE
$2.65B
| $3.3M | ﹤0.01% |
157,526
+85,358
| +118% | +$1.92M |
|
1500
Smith & Wesson
SWBI
$655M
| $3.29M | ﹤0.01% |
229,755
+144,635
| +170% | +$1.76M |
|
Similar funds
Marshall Wace's Q1 2026 Portfolio in Review
As of Q1 2026, Marshall Wace held 3,811 positions worth $100B, down 8.6% from $110B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Marshall Wace withdrew a net $5.83B in Q1 2026, closing 681 positions and reducing 974 holdings. Its most notable exit was Vanguard S&P 500 ETF, an estimated $2.87B position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Marshall Wace opened a new position in State Street SPDR Portfolio S&P 500 ETF worth $3.8B.
- Marshall Wace's largest Q1 2026 buy was State Street SPDR Portfolio S&P 500 ETF: 49,650,246 shares worth $3.8B.
- Marshall Wace added most to Chevron in Q1 2026, an estimated $527M increase.
- Marshall Wace's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $4.21B.
- Marshall Wace fully exited Vanguard S&P 500 ETF in Q1 2026, selling an estimated $2.87B.
- Marshall Wace's ten largest holdings make up 32% of its $100B portfolio in Q1 2026.
- Marshall Wace opened 911 new positions and closed 681 in Q1 2026.
- Marshall Wace's portfolio value fell 8.6% quarter-over-quarter to $100B.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.